Innate PharmaIPHA +0.14%41 Debt-to-Equity is -1.04 as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 966 Biotechnology companies, Innate Pharma ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Innate Pharma's Debt-to-Equity or its related term are showing as below:
IPHA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.04 Med: 0.1 Max: 3.51
Current: -1.04
During the past 13 years, the highest Debt-to-Equity Ratio of Innate Pharma was 3.51. The lowest was -1.04. And the median was 0.10.
IPHA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs IPHA: -1.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Innate Pharma Debt-to-Equity Related Terms
Innate Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Innate Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Debt-to-Equity of -1.04 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #999999 out of 966 companies in the Biotechnology industry.
Is Innate Pharma's Debt-to-Equity too high?
Innate Pharma's current Debt-to-Equity is -1.04. Based on the distribution chart, Innate Pharma ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #999999 out of 966 companies for Debt-to-Equity. This places Innate Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Debt-to-Equity is -1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.79 — trading 1095% above its estimated fair value. The current Debt-to-Equity is -1.04. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Debt-to-Equity is -1.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.79 is trading 1095% above its estimated GF Value™ of $0.15.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Debt-to-Equity: -1.04
GF Value™: $0.15 vs. price of $1.79 (1095% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
